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Summary
 
C-reactive protein (CRP) is an acute phase serum protein that shares several functions with
immunoglobulin (Ig)G including complement activation and binding to receptors on mono-
cytes and neutrophils. The identity of the receptor for CRP has been the target of extensive re-
search. We previously determined that CRP binds to the high affinity receptor for IgG, Fc
 
g
 
RI
(CD64). However, this interaction could not account for the majority of binding of CRP to
neutrophils or monocytic cells. We now determine that CRP also interacts with Fc
 
g
 
RIIa
(CD32), the low affinity receptor for IgG on monocytes and neutrophils. COS-7 cells were
transfected with a construct containing the human Fc
 
g
 
RIIA cDNA. CRP binding and the
presence of CD32 were detected by mAb and analyzed by two-color flow cytometry. Cells ex-
pressing CD32 bound CRP in a dose-dependent and saturable manner consistent with recep-
tor binding. CRP bound to transfectants and K-562 cells with similar kinetics, and in both
cases binding was completely inhibited by aggregated IgG. On monocytic cell lines, treatment
with Bt
 
2
 
cAMP increased Fc
 
g
 
RII expression and enhanced CRP binding. CRP also specifically
precipitated Fc
 
g
 
RI and Fc
 
g
 
RII from the monocytic cell line, THP-1. It is suggested that the
major receptor for CRP on phagocytic cells is Fc
 
g
 
RII.
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C
 
-reactive protein (CRP) is an acute phase serum pro-
tein in humans and a member of the pentraxin family
of proteins (1). Serum concentrations of CRP increase
from less than one to hundreds of micrograms per milliliter
as part of the inflammatory response to infection or acute
injury. Functionally, CRP shares many properties with
IgG. These properties include specific ligand binding, acti-
vation of the complement cascade through the binding of
C1q (2), and opsonic activity (3–5).
The presence of a receptor for CRP was first suggested
by reports of opsonic activity of CRP (3–5). Several inves-
tigators have reported the presence of a unique receptor for
CRP on mononuclear cells and neutrophils. Tebo et al. (6)
and Zahedi et al. (7) concluded that two receptors for CRP
were present on mononuclear cells in humans and mice. It
was noted that there was some possible association with Fc
receptors (FcRs) as IgG could inhibit binding. Other au-
thors also noticed a functional interaction with FcRs but
maintained that a specific receptor for CRP was also
present (8, 9). Our laboratory reported that CRP interacted
specifically with the high affinity receptor for IgG, Fc
 
g
 
RI
(10, 11). However, it was apparent that this receptor could
not account for all the binding to mononuclear cells and
neutrophils as cells lacking Fc
 
g
 
RI were also capable of
binding CRP, and upregulation of Fc
 
g
 
RI did not signifi-
cantly enhance CRP binding. Examination of the binding
pattern of CRP with various cell lines and blood cell popu-
lations suggested to us that CRP might bind to Fc
 
g
 
RII. In
the study presented here, we demonstrate binding of CRP
to Fc
 
g
 
RIIa expressed in COS-7 cells by transient transfec-
tion. Studies of monocytic cell lines done in parallel indi-
cate that Fc
 
g
 
RIIa is responsible for the majority of CRP
binding to these cells. It is suggested that Fc
 
g
 
RIIa is the
previously described “unique” receptor for CRP.
 
Materials and Methods
 
Preparation of CRP.
 
Human CRP was purified from human
pleural fluids exactly as previously described (12). The purity of
the preparation was determined by 12% SDS-PAGE. No con-
taminating proteins were detected on overloaded gels.
 
Reagents and Antibodies.
 
The monoclonal anti-CRP antibody,
2C10, was the gift of Dr. Larry Potempa (ImmTech, Evanston,
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IL) and was used as a hybridoma tissue culture supernatant.
FITC-conjugated F(ab
 
9
 
)
 
2
 
 goat anti–mouse IgG (FITC-GAM) was
obtained from Caltag Labs. or from ICN. Affinity-purified F(ab
 
9
 
)
 
2
 
PE-GAM was obtained from Caltag Labs. Aggregated IgG (agg-
IgG) was prepared from human IgG (Sigma Chemical Co.) by
incubation at 63
 
8
 
C for 30 min at 10–12 mg/ml. AT10 (an anti-
CD32 mAb) and FITC-AT10 were purchased from Serotec.
FITC-FLI8.26 (2003) (an anti-CD32 mAb) was purchased from
PharMingen. This antibody was absorbed with mock-transfected
COS-7 cells for 30 min on ice to remove nonspecific binding.
PE-C1KM5 (an anti-CD32 mAb) was purchased from Caltag
Labs. Anti-CD64 mAb 197 and anti-CD32 mAb IV.3 were pur-
chased from Medarex. Protein A–Sepharose CL6B and Affigel 15
were purchased from Sigma Chemical Co. and Bio-Rad, respec-
tively. Bt
 
2
 
cAMP was purchased from Sigma Chemical Co.
 
Cell Culture.
 
The human erythroleukemia cell line K-562,
the human monocytic cell lines THP-1 and U-937, and COS-7
cells were obtained from the American Type Culture Collection.
All cell lines were maintained in RPMI with 10% FCS (Hyclone)
and 50 
 
m
 
g/ml gentamycin, except for COS-7 cells, which were
maintained in DMEM with 10% FCS and 50 
 
m
 
g/ml gentamycin.
 
Treatment of U-937 Cells with Bt
 
2
 
cAMP.
 
Cells were counted
and resuspended at 0.3 
 
3
 
 10
 
6
 
 cells/ml in medium containing 1 mM
Bt
 
2
 
cAMP, and incubated for 60 h before analysis.
 
Cell Transfections.
 
The human Fc
 
g
 
RIIA cDNA clone in the
pcDSR
 
a
 
296 transient transfection vector (13) was obtained from
Dr. Kevin Moore (DNAX Research Institute, Palo Alto, CA).
Cells were transfected using the GenePORTER™ transfection
reagent from Gene Therapy Systems Inc. Control cells received
GenePORTER™ reagent only. 6-well tissue culture plates were
seeded with 2.5 
 
3
 
 10
 
5
 
 cells/well and cultured for 18–24 h until
the cells were 70–80% confluent. Transfection was performed ac-
cording to the manufacturer’s protocol, except cells were centri-
fuged to increase transfection efficiency. Plates were centrifuged
at 300 
 
g
 
 for 10 min at 21
 
8
 
C and then incubated at 37
 
8
 
C for 5 h.
Cells were cultured overnight in DMEM with 10% FCS. 18 h af-
ter transfection, cells were detached using PBS
 
 
 
containing 5 mM
EDTA and replated on 100-mm tissue culture plates (two 100-mm
tissue culture plates for cells from each 6-well plate) and cultured
in DMEM. Flow cytometric assays were performed 66–78 h after
transfection. The percentage of transfected cells was 75–85% as
determined using either FITC-FLI8.26 or PE-C1KM5.
 
CRP Binding Assay.
 
Cells were washed twice in ice-cold
PBS containing 0.05% azide and 0.1% globulin-free BSA (PAB).
Between 5 
 
3
 
 10
 
5
 
 and 10
 
6
 
 cells per tube were washed with 1 ml
of ice-cold PAB. Cells were pelleted at 180 
 
g
 
 for 5 min at 4
 
8
 
C
and resuspended in PAB with CRP at the concentrations indi-
cated in a total volume of 80 
 
m
 
l. Cells were incubated for 1 h in
the presence of CRP, then washed twice with 1 ml of PAB. Cells
were then incubated for 30 min at 4
 
8
 
C with mAb 2C10 culture
supernatant. Cells were washed twice with 1 ml PAB and then
incubated with PE-GAM (1 
 
m
 
g/10
 
6
 
 cells) or FITC-GAM (a 1:100
final dilution) for 30 min. After this last incubation, cells were
washed twice with 1 ml PAB as above and then resuspended in
0.4–0.5 ml PAB for analysis by flow cytometry. Fc
 
g
 
RI levels
were determined using mAb 32.2 and PE-GAM. Levels of Fc-
 
g
 
RII were determined by binding of FITC-AT10. The percent-
age of dead cells was determined using 7-Aminoactinomycin D
(Molecular Probes). To test inhibition by aggIgG, cells were in-
cubated with aggIgG at an increasing concentration for 30 min
before the addition of CRP. There was no significant change in
the fluorescence of the secondary antibodies in the presence of
aggIgG.
 
Flow Cytometry.
 
Cells were analyzed using a Becton Dickin-
son FACSCalibur
 
®
 
 flow cytometer equipped with CellQuest
software (Becton Dickinson). The population analyzed was gated
by forward and side scatter to exclude dead cells. A minimum of
30,000 cells was collected. For all measurements of CRP binding,
the binding of 2C10 and the anti–mouse secondary antibody
were subtracted. Results are presented as the geometric mean
channel fluorescence (gMCF).
 
Precipitation of Cell Surface Receptors.
 
THP-1 cells were treated
with 50 
 
m
 
g/ml pronase (Calbiochem) for 30 min at 37
 
8
 
C,
washed, and radiolabeled with 
 
125
 
I using lactoperoxidase (14).
Membrane extracts were prepared at 5 
 
3
 
 10
 
7
 
 cells/ml using 1%
NP-40 in PBS with 1 mM AEBSF, 1 
 
m
 
M pepstatin A, 10 
 
m
 
M
E-64, 10 
 
m
 
M bestatin, 100 
 
m
 
M leupeptin, and 2 
 
m
 
g/ml aprotinin
(lysis buffer). CRP beads were prepared by coupling 18 mg
CRP/ml Affigel 15 according to the manufacturer’s protocol.
Antibody beads were prepared by incubation of 5 
 
m
 
g anti-CD32
mAb (IV.3 or AT10) or anti-CD64 mAb 197 with 15 
 
m
 
l protein
A–Sepharose. 2.5 
 
3
 
 10
 
6
 
 cell equivalents were incubated with
CRP beads, anti-CD32 Sepharose, or anti-CD64 Sepharose in
Figure 1. CRP binds to COS–7 cells transfected with the FcgRIIA
cDNA, and to K-562 cells with similar kinetics. Cells were incubated
with increasing doses of CRP and binding was detected with 2C10 and
PE-GAM, as described in Materials and Methods. Results are expressed as
the increase in gMCF compared with the secondary antibody controls.
(A) COS-7 cells transfected with the FcgRIIA plasmid or pcDSRa296,
or mock-transfected. Specific binding was determined by subtracting
gMCF of mock-transfected cells from gMCF of transfected cells. (B) K-562
cells. 
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lysis buffer for 4 h at 4
 
8
 
C. The beads were then washed four
times with lysis buffer and once with 0.1% NP-40 in the same
buffer. The samples were boiled for 3 min in Laemmli’s sample
buffer and run on 4–20% gradient SDS-PAGE gels (Novex). The
gels were dried and autoradiography was performed using a
Storm imaging system (Molecular Dynamics).
 
Data Analysis.
 
The binding kinetics of CRP to cells were an-
alyzed using GraphPad PRISM™ software (GraphPad Software,
Inc.). ImageQuant software (Molecular Dynamics) was used for
quantitation of radioactive bands. Experiments were repeated at
least twice.
 
Results
 
Binding of CRP to Transfected COS-7 Cells and to K-562
Cells.
 
Transfection of COS-7 cells with pcDSR
 
a
 
296
containing the cDNA for CD32 resulted in 70–85% of cells
expressing the CD32 marker. When these cells were incu-
bated with CRP, a dose-dependent and saturable binding
of CRP was seen (Fig. 1 A). The binding of CRP was fit-
ted to a single site model using GraphPad Prism™ soft-
ware. Saturation was predicted at 100 
 
m
 
g/ml with an ap-
parent equilibrium binding constant (
 
K
 
D
 
) of 6.6 
 
3
 
 10
 
2
 
8
 
 M
(7.6 
 
m
 
g/ml). This binding curve is similar to the binding of
CRP to K-562 cells, which express Fc
 
g
 
RII as the only
FcR (Fig. 1 B). The apparent 
 
K
 
D
 
 is 9.7 
 
3
 
 10
 
2
 
8
 
 M (11.2
 
m
 
g/ml) with saturation at 
 
z
 
100 
 
m
 
g/ml. Background bind-
ing to mock-transfected cells was not above baseline bind-
ing of secondary antibody. The apparent affinity of CRP
for transfected and K-562 cells was significantly higher than
the reported values for IgG binding to Fc
 
g
 
RII (
 
K
 
D
 
 
 
.
 
10
 
2
 
7
 
 M) (15) and similar to the previously reported figure
for CRP binding to K-562 cells (3.8 
 
3
 
 10
 
2
 
8
 
 M) (6). In
separate experiments using 
 
125
 
I-labeled aggIgG, an apparent
 
K
 
D
 
 of 23 
 
m
 
g/ml was measured (data not shown).
Binding of CRP to transfected cells was also examined
by two-color analysis to confirm that CRP bound to cells
Figure 2. Analysis of CRP bind-
ing to transfected COS-7 cells by
two-color flow cytometry. COS-7
cells were transfected with the
FcgRIIA plasmid, pcDSRa296.
Mock-transfected cells received no
DNA. Cells were incubated with
200  mg/ml of CRP and binding was
detected with 2C10 and PE-GAM as
described in Materials and Methods.
Levels of FcgRII were determined
by binding of FITC-AT10. A, B, C,
and D, transfected; E, F, G, and H,
mock-transfected. A and E, staining
with 2C10 and PE-GAM; B and
F, staining for CD-32 only; C and
G, staining for CRP only; D and H,
staining for CRP and CD32.
Figure 3. CRP binding to FcgRIIa is in-
hibited by aggIgG. K-562 cells or COS-7
cells transfected with the FcgRIIA plasmid,
pcDSRa296, were incubated with 25 mg/ml of
CRP in the presence of increasing concentra-
tions of aggIgG. CRP binding was detected
with 2C10 and PE-GAM as described in Mate-
rials and Methods. Results are expressed as the
increase in gMCF compared with the secondary
antibody controls. The solid line represents
binding of CRP to K-562 cells and the dotted
line represents the binding of CRP to trans-
fected COS cells in the absence of aggIgG.588 CRP Binds to Human FcgRIIa
expressing CD32 (Fig. 2). Single color staining with anti-
CD32 (Fig. 2 B) or CRP (Fig. 2 C) showed staining of
72% (with a background binding of 6% to mock-trans-
fected) and 63% (with a background binding of ,1% of
mock-transfected) of transfected cells, respectively. In the
two-color analysis, CRP binding to CD32-transfected
COS cells directly correlated with anti-CD32 binding with
52% of the cells stained for both markers (Fig. 2 D).
Binding of CRP to CD32-Transfected COS-7 Cells and to
K-562 Cells Is Blocked by IgG. To determine if CRP was
binding to the same site on FcgRII as IgG, the effect of
aggIgG on CRP binding was examined. As shown in Fig. 3,
aggIgG inhibited CRP binding to K-562 cells in a dose-
dependent manner with 50% inhibition at z80 mg/ml of
aggIgG. This finding is consistent with previous reports by
us (10, 11) and others (5–7) that aggIgG effectively blocks
CRP binding to its receptor. A nearly identical inhibition
profile was obtained using aggIgG to inhibit CRP binding
to CD32-transfected COS cells (Fig. 3). For both cell
types, aggIgG did not affect the background binding of the
secondary antibodies measured in the absence of CRP.
Enhanced Binding of CRP to Bt2cAMP-treated U-937
Cells. Agents that affect the differentiation state may alter
the expression of FcR on monocytic cell lines. The U-937
cell line expresses FcgRI and FcgRII. Exposure of U-937
cells to Bt2cAMP has been reported to decrease the expres-
sion of FcgRI while increasing the expression of FcgRII
(17). We tested the effect of exposure of U-937 cells to
Bt2cAMP on the amount of binding of CRP. Since both
FcgRI and FcgRII bind CRP, a change in the level of
CRP binding might suggest that one or the other receptor
is more important in CRP binding. As shown in Fig. 4,
Bt2cAMP decreased the expression of FcgRI and increased
the expression of FcgRII as previously reported. Associated
with this increase in FcgRII, a marked increase in CRP
binding was seen (Fig. 4). Thus, the binding of CRP to
FcgRII may be quantitatively more important than the
binding to FcgRI.
Precipitation of FcR by CRP. In an attempt to identify
proteins reacting with CRP on FcR-bearing cells, receptor
precipitation studies were performed. THP-1 cells express
both FcgRI and FcgRII. Attempts to immunoprecipitate
surface-labeled proteins with immobilized CRP showed
weak and nonspecific bands. However, it had previously
been determined that the interaction of IgG with FcgRII
could be enhanced by pronase treatment of cells (18). We
recently determined that pronase treatment of FcgRII-
bearing cells also markedly increases the binding of CRP
(Stein, M.-P., J.C. Edberg, R.P. Kimberly, E.K. Mangan,
D. Bharadwaj, C. Mold, and T.W. Du Clos, manuscript
submitted for publication). When pronase-treated cells
were radiolabeled and precipitated with CRP, distinct
binding of two major bands was seen. These bands with Mr
of 70 and 42 kD corresponded to the bands precipitated by
mAb to CD64 and CD32 (Fig. 5).
Discussion
The binding of CRP to FcgRII was demonstrated in
cells transfected with the gene for human FcgRIIA. Bind-
ing was dose dependent and resembled the binding of CRP
to the erythroleukemia cell line, K-562, which expresses
FcgRII as the only FcR. Because accessory molecules are
not necessary for the expression of FcgRII, it is probable
that CRP binds directly to FcgRII and not to associated
molecules. This finding was also confirmed by the com-
plete inhibition of CRP binding to K-562 and CD32-
transfected COS cells by aggIgG. The binding and inhibi-
Figure 4. Treatment of U-937 cells with
Bt2cAMP increases CRP binding. U-937
cells were grown for 60 h in medium con-
taining 1 mM Bt2cAMP before analysis of
CRP binding. CRP binding was detected
with 2C10 and PE-GAM as described in
Materials and Methods. Results are ex-
pressed as the increase in gMCF compared
with the secondary antibody controls. (Inset)
FcgRI and FcgRII levels were measured us-
ing mAb 32.2 and PE-F(ab9)2 GAM IgG
and PE-C1KM5, respectively.589 Bharadwaj et al. Brief Definitive Report
tion curves for the two cell types were similar. These studies
suggest that not only is CRP capable of binding to
FcgRII, there is reason to believe it is the only receptor on
K-562 cells, which express only the low affinity IgG receptor.
Precipitation of surface-labeled proteins from the mono-
cytic cell line THP-1 with immobilized CRP demon-
strated bands with the Mr of FcgRI (70 kD) and FcgRII
(42 kD). The 42 kD band could be precleared from the ly-
sate by adsorption with immobilized anti-CD32 mAb,
confirming its identity as FcgRII (data not shown).
Our previous studies demonstrated that CRP also binds
to the high affinity receptor for IgG, FcgRI (10, 11). These
studies revealed that mononuclear cells were capable of
binding CRP through FcgRI, but FcgRI could not ac-
count for all of the binding. Mononuclear cells and mono-
cytic cell lines express FcgRII as well as FcgRI. Our cur-
rent findings demonstrate the precipitation of both FcgRI
and FcgRII from the THP-1 cell line, after pronase activa-
tion of FcgRII. However, treatment of U-937 cells with
Bt2-cAMP, which increased FcgRII expression, also increased
CRP binding, whereas treatment of U-937 cells with
rIFN-g to increase FcgRI did not increase CRP binding
(our unpublished results). In our previous studies, binding
to U-937 cells was completely inhibited by aggIgG but
only 20% inhibited by monomeric IgG (10). These findings
indicate that CRP binding to FcgRII accounts for most of
the binding to these monocytic cell lines.
Taken together, our results support the hypothesis that
CRP binding to phagocytic cells is mediated by FcRs. This
is further supported by studies in a mouse model in which
knockout mice lacking all three FcRs fail to bind CRP
(Stein, M.-P., C. Mold, and T.W. Du Clos, manuscript in
preparation). These findings thus suggest that there is no
unique receptor for CRP, as was postulated previously, and
that the major receptor for CRP on monocytic cells is Fc-
gRIIa.
In conclusion, the acute phase protein CRP, an ancient
mediator of innate immunity, binds to FcgRII, considered
a receptor for the acquired immune response, with an af-
finity comparable to that of IgG. It is attractive to speculate
that during the acute phase response, high levels of circu-
lating CRP may influence signaling by IgG complexes
through FcgRII. It remains to be determined whether
CRP will have a positive or negative influence. Future
studies will examine the direct effect of CRP on receptor
activation and the effect of CRP on IgG-mediated sig-
naling.
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